Skip to main content

United Therapeutic(UTHR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low525.86
Day High548.12
Open:525.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: United Therapeutic

Select a category then submit the form to load news
Tipranks
Wells Fargo Reaffirms Their Hold Rating on United Therapeutics (UTHR)
Tipranks
Analysts Conflicted on These Healthcare Names: Veeva Systems (VEEV) and United Therapeutics (UTHR)
Tipranks
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH), Becton Dickinson (BDX) and United Therapeutics (UTHR)
Tipranks
Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), United Therapeutics (UTHR)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: United Therapeutics (UTHR), Pennant Group (PNTG)
Tipranks
United Therapeutics Earnings Call Signals Growth Ahead
Tipranks
Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), TG Therapeutics (TGTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Alnylam Pharma (ALNY)
StockStory
2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm
SFM
Tipranks
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS) and United Therapeutics (UTHR)
Stock Target Advisor
Market Analysis for February 26th, 2026
Market Analysis for February 26th, 2026
StockStory
Why United Therapeutics (UTHR) Shares Are Sliding Today
UTHR
Motley Fool
Stock Market Today, Feb. 25: Nasdaq Gains 1.3% As Nvidia Reignites AI Optimism
StockStory
United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates
UTHR
StockStory
United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For
UTHR
Motley Fool
6 Stock Ideas for the Next 5 Years
Tipranks
United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial
Zacks Investment Research
Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
Merck's Subdued 2026 Outlook: What it Means After Q4 Results?
StockStory
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
UTHR
Motley Fool
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24%
Motley Fool
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding
Zacks Investment Research
Merck's Non-Oncology Drugs Q4 Performance: What to Expect
Merck's Non-Oncology Drugs Q4 Performance: What to Expect
StockStory
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
UTHR
Tipranks
United Therapeutics appoints new director, updates bylaws
Tipranks
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Omada Health, Inc. (OMDA) and United Therapeutics (UTHR)
StockStory
3 Market-Beating Stocks to Target This Week
KLAC
Motley Fool
Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing
Motley Fool
Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase
Tipranks
Leerink Partners Reaffirms Their Buy Rating on United Therapeutics (UTHR)
Tipranks
United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension
StockStory
2 Cash-Heavy Stocks to Target This Week and 1 We Question
BRZE
Tipranks
UBS Keeps Their Buy Rating on United Therapeutics (UTHR)

Profile

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.